Collagen Stimulators
Collagen stimulator is a practical umbrella term, not a promise that the products inside it behave alike. PLLA, PDLLA, calcium hydroxylapatite (CaHA), and polycaprolactone (PCL) products differ in physical form, carrier, preparation, immediate correction, intended use, and regulatory status.
For product selection and treatment planning, the full formulation matters more than the material acronym alone.
Four material groups at a glance
Section titled “Four material groups at a glance”| Material | Common aesthetic presentation | Immediate correction | Initial reference products | Main interpretation issue |
|---|---|---|---|---|
| PLLA | Reconstituted polymer-particle suspension | Initial fluid-related correction is not the final tissue response | Sculptra; Lanluma | Preparation and presentation remain brand-specific |
| PDLLA | PDLLA particles, alone or combined with non-cross-linked HA | Product-dependent | AestheFill; Juvelook family | Particle architecture and hybrid composition differ |
| CaHA | CaHA microspheres suspended in a gel carrier | Yes, when the carrier provides structural correction | Radiesse | Carrier behavior and microsphere-related tissue response are distinct |
| PCL | Microspheres in a gel carrier or a solubilized-polymer system | Product-dependent | Ellansé; Gouri comparison context | Physical form changes the product category in practice |
The four groups are widely discussed together in the clinical literature, but comparative evidence is uneven and often product-specific. A 2026 systematic review of facial PLLA and CaHA studies illustrates both the available clinical evidence and the difficulty of treating an ingredient family as a single standardized intervention (facial PLLA and CaHA systematic review 🔗).
Product and company map
Section titled “Product and company map”| Material | Brand or family | Company context | Why it belongs in the first map |
|---|---|---|---|
| PLLA | Sculptra | Galderma | Established PLLA reference product with regulator-hosted documentation |
| PLLA | Lanluma | Sinclair commercial context | A separate PLLA presentation used in face and body discussions |
| PDLLA | AestheFill | REGEN Biotech | PDLLA product without being flattened into a hybrid PDLLA + HA category |
| PDLLA + HA | Juvelook family | VAIM | Product family with distinct PDLLA and HA quantities by presentation |
| CaHA | Radiesse | Merz Aesthetics | CaHA microspheres in a gel carrier with current regulator-hosted instructions |
| PCL | Ellansé | Sinclair | PCL microspheres suspended in a CMC-containing carrier gel |
| PCL | Gouri | Dexlevo | Early comparison anchor for a manufacturer-described solubilized PCL system |
Company names in this table indicate the first commercial relationship to investigate. They do not automatically mean physical manufacturer, legal manufacturer, approval holder, or distributor in every market.
Regional regulation
Section titled “Regional regulation”Approval and intended use belong to a product, presentation, jurisdiction, and document date—not to PLLA, PDLLA, CaHA, or PCL as a material class.
| Region | Primary route used in this index | Main reading boundary |
|---|---|---|
| United States | FDA PMA record, supplement, labeling, and SSED | A supplement may change manufacturing or labeling without adding an indication |
| European Union | MDR/MDD conformity evidence, notified-body information, EUDAMED, current IFU | CE marking is conformity assessment, not one centralized product approval |
| South Korea | MFDS product record or certificate plus current Korean product information | Product approval, manufacturing license, GMP, and advertising review are separate facts |
The regional overview records what is confirmed, company-reported, historically documented, or not identified as of July 31, 2026.
Treatment objectives
Section titled “Treatment objectives”Define the desired change before comparing products. “Collagen stimulation” alone does not say whether the objective is focal structure, broad contour, elasticity, surface texture, hydration, or a staged combination.
| Objective page | Decision it supports |
|---|---|
| Structural correction | Separates immediate carrier support, transient suspension volume, and delayed tissue response |
| Skin quality | Converts vague improvement claims into observable or measured attributes |
| Face vs body | Keeps anatomy, surface area, evidence, and regional labeling specific |
| Immediate vs delayed | Aligns counseling, photography, reassessment, and outcome attribution with time |
The objective framework is a selection aid, not a product ranking or a treatment protocol.
Focused comparisons
Section titled “Focused comparisons”These pages answer a defined product-selection question without turning unlike formulations into a ranking.
| Comparison | Practical question |
|---|---|
| PLLA vs PDLLA | What does polymer stereochemistry explain, and what still depends on the finished product? |
| Sculptra vs Lanluma | How do two PLLA product families differ in presentation, documentation, and use context? |
| AestheFill vs Juvelook | How does a PDLLA product differ from a multi-presentation PDLLA + HA family? |
| Ellansé vs Gouri | Why are particulate and manufacturer-described solubilized PCL systems not interchangeable? |
| Ready-to-use vs reconstituted | Which handling checks change before the syringe reaches the patient? |
Clinical practice framework
Section titled “Clinical practice framework”Product knowledge becomes clinically useful only when it is connected to screening, consent, documentation, follow-up, and emergency readiness.
| Stage | Working page | Core question |
|---|---|---|
| Before selection | Patient selection | Is the objective appropriate, and what history changes the plan or timing? |
| Before treatment | Consultation and consent | Does the patient understand the exact product, expected phases, alternatives, and material risks? |
| Across the episode | Documentation and follow-up | Could another clinician reconstruct what was used, where, and when? |
| New palpable finding | Nodules and delayed reactions | Is the finding early or delayed, inflammatory or non-inflammatory, and is infection plausible? |
| Suspected ischemia | Vascular and visual emergencies | Is the emergency pathway activated without delay? |
The practice framework connects these stages without replacing local law, the current IFU, accredited training, or an established emergency protocol.
Read the formulation before the category
Section titled “Read the formulation before the category”Material
Section titled “Material”Material identity helps explain degradation chemistry and broad tissue-response concepts. It does not establish a product’s preparation, placement, duration, or safety profile by itself.
Physical form
Section titled “Physical form”Microspheres, porous particles, hybrid particle–HA formulations, and solubilized polymers are not interchangeable presentations. The PCL comparison makes this especially visible: Sinclair’s safety document describes Ellansé as PCL microspheres in a carrier gel, while Dexlevo describes Gouri as fully solubilized PCL (Sinclair SSCP 🔗; Dexlevo 🔗).
Carrier and immediate effect
Section titled “Carrier and immediate effect”The carrier may create temporary hydration, spread, or immediate structural correction while the particulate or polymer component is discussed in relation to a later tissue response. Those phases should not be reported as one undifferentiated “result.”
Preparation
Section titled “Preparation”Ready-to-use syringes and products requiring reconstitution introduce different handling questions. Preparation volume, hydration time, mixing, storage, and use window must come from the exact product information for the relevant market.
Approval and practice
Section titled “Approval and practice”Common clinical use can extend beyond a local approved indication. Injectable Index keeps regulator-approved use, manufacturer instructions, published technique, consensus practice, and off-label practice visibly separate.
A practical reading path
Section titled “A practical reading path”- Start with the material page to understand the family.
- Move to the exact product before making assumptions about preparation or performance.
- Check the company-role and regional-approval context.
- Compare products only across defined fields supported by compatible sources.
- Return to the current local IFU and formal training before clinical use.
Vascular events, visual loss, infection, inflammatory nodules, and granulomatous reactions require product-aware recognition and management. A 2026 systematic review specifically includes PLLA, PDLLA, CaHA, and PCL in its assessment of visual loss after biostimulator injection (visual-loss systematic review 🔗).